Market Overview

FDA Advisory Committee Votes to Recommend Isis' KYNAMRO

Share:
Related SNY
Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes
US Stock Futures Drop; All Eyes On Jobs Report
How Do Top 10 Healthcare Dogs Get 9.14% More Net Gains From 5 Lowest Priced By September 2016? (Seeking Alpha)

Genzyme,
a Sanofi company (NYSE: SNY), and Isis Pharmaceuticals
(NASDAQ: ISIS), announced today that the Endocrinologic and
Metabolic Drugs Advisory Committee of the U.S. Food and Drug
Administration (FDA) voted 9 to 6 that Genzyme had provided
sufficient efficacy and safety data to support the marketing of KYNAMRO™
(mipomersen sodium) for the treatment of patients with Homozygous
Familial Hypercholesterolemia (HoFH). Many people with HoFH have
aggressive cardiovascular disease beginning in childhood, and even with
today's therapies remain at significant risk of cardiovascular events.

"We are very encouraged by the support for KYNAMRO at today's Advisory
Committee meeting, which marks a significant and positive step in our

See full press release

Posted-In: News Guidance Contracts Asset Sales Management Global

 

Related Articles (ISIS + SNY)

Get Benzinga's Newsletters